Mithra and Searchlight Pharma announce launch of Haloette® in Canada

Following the successful launch of Mithra’s innovative contraceptive pill Nextstellis® last year, Searchlight Pharma is pleased to further expand its growing footprint in Women’s Health with the commercialization of Haloette® . Currently, the Canadian vaginal contraceptive ring market is worth approximately CAD $11.5 million (EUR 8 million) a year (1), represented exclusively by the originator Nuvaring® (2). Haloette® is a new affordable option for women that was approved by Health Canada in September 2021 and is now available in pharmacies across Canada.

Developed and manufactured by European women’s health expert and innovator Mithra, Haloette® eliminates the need for refrigerated conditions prior to being dispensed to patients. This provides a competitive advantage for both wholesalers and pharmacies, by reducing transport, storage costs, and the need for cold chain storage. Furthermore, it provides a more convenient option for distributors, pharmacists and patients.

“We are delighted to partner with Mithra once again in order to offer Canadian women an additional choice in addressing their contraception needs, said Mark Nawacki, President & CEO of Searchlight Pharma. “Since making Haloette® available across Canada this past December, interest has been very high, as evidenced by rapid product uptake at major wholesalers and pharmacy banners throughout Canada, as well as the many formulary listings with private and public payers, including the Public Prescription Drug Insurance Plan (RAMQ) in Quebec.”

“It’s thrilling to team up once again with Searchlight Pharma to bring innovative contraceptive alternatives to Canadian women”, said Leon Van Rompay, CEO Mithra. “Just a few months after the Canadian launch of Nextstellis® , we are now also providing women with access to the first generic product of a contraceptive ring in this first region in North America. Our Mithra CDMO pursues the production of all Myring® commercial batches orders for a range of new commercial launches planned for 2022”.

(1) IQVIA 2021

(2) Nuvaring® is registered trademark of N.V. Organon